Supplementary Table 1: Summary of Pharmacokinetic data[a]

Parameter	Absence of Rosuvastatin	Presence of Rosuvastatin	P-value[b]
Imatinib			
AUC_{Tau} (µg*h/mL)	37.6 ± 19.8 (34.3)	37.0 ± 21.8 (33.2)	0.80
Cmin (ng/mL)	931 ± 457 (839)	935 ± 590 (832)	0.97
Cmax (ng/mL)	2717 ± 1393 (2464)	2616 ± 1661 (2335)	0.65
$T\frac{1}{2}_z$ (h)	19.1 ± 2.81 (18.9)	18.9 ± 4.60 (18.4)	0.81
CGP74588			
AUC_{Tau} (µg*h/mL)	7.18 ± 3.07 (6.48)	6.62 ± 3.12 (5.91)	0.27
Cmin (ng/mL)	221 ± 104 (196)	210 ± 110 (183)	0.58
Cmax (ng/mL)	476 ± 206 (430)	419 ± 199 (375)	0.077
$T\frac{1}{2}_z$ (h)	39.0 ± 12.8 (37.2)	33.1 ± 6.42 (32.5)	0.15
AUC Ratio $_{CGP/Imatinib}$	0.197 ± 0.056 (0.189)	0.187 ± 0.060 (0.178)	0.065

[a]Pharmacokinetic data are shown as mean values ± standard deviation (geomean). [b]As calculated in a paired analysis (T-test).
AUC_{Tau}, area under the plasma concentration time curve for a dosing interval; Cmin, imatinib or CGP74588 trough plasma level; Cmax, imatinib or CGP74588 peak plasma level; $T\frac{1}{2}_{z,}$ terminal elimination half-life.